Laboratory Analytical Instruments · SIC 3826

Lifeloc Technologies, Inc

LCTC

Watch

Latest revenue

$2.3M

as of 2026-03-31

Latest net income

$-152.7K

as of 2026-03-31

Net margin

-6.7%

as of 2026-03-31

Price · 5Y

-11.0% / yr 24.8 pts / yr vs S&P 500 44.1% total
Compare:

Live market

delayed ≤15 min
$2.18
0.00%
Market cap
$6.0M
Enterprise value
$6.0M
P/E (trailing)
Forward P/E
P/B
Dividend yield
0.0%
52-wk high
$5.51
52-wk low
$1.75
Beta
Shares out
2.8M

5-year trend

What this company does

AI

Item 1. Business Overview Lifeloc Technologies, Inc., a Colorado corporation ("Lifeloc" or the "Company"), is a Colorado-based developer, manufacturer and marketer of portable hand-held and fixed station breathalyzers and related accessories, supplies and education. We design, produce and sell fuel-cell based breath alcohol testing equipment. We compete in all major segments of the portable breath alcohol testing instrument market, including law enforcement, workplace, corrections, original equipment manufacturing ("OEM") and consumer markets. In addition, we offer a line of supplies, accessories, services, and training to support customers' alcohol testing programs. We sell globally…

AI summary unavailable — showing raw filing excerpt

Generated from LCTC's filing dated 2026-03-27

Key risks

AI

Item 1A. Risk Factors You should carefully consider the risk factors described below. If any of the following risk factors actually occur, our business, prospects, financial condition or results of operations would likely suffer. In such case, the trading price of our common stock could fall, resulting in the loss of all or part of your investment. You should look at all these risk factors in total. Some risk factors may stand on their own. Some risk factors may affect (or be affected by) other risk factors. You should not assume we have identified these connections. You should not assume that we will always update these and future risk factors in a timely manner. Except as required under…

AI summary unavailable — showing raw filing excerpt

Generated from LCTC's filing dated 2026-03-27

Profitability

Gross margin

40.3%

0.0%

Operating margin

-13.6%

17.4%

Net margin

-27.4%

121.9%

Return on equity

-60.2%

255.9%

Return on assets

-36.9%

206.1%

Leverage

Debt / equity

0.63×

56.8%

Long-term debt / equity

0.26×

43.5%

Debt / assets

38.6%

34.9%

Earnings tracker

QuarterRevenueYoYNet incomeYoYNet margin

Q1 2026

2026-03-31

$2.3M+0.7%$-152.7K+47.8%-6.7%

Q4 2025

2025-12-31

$2.3M+19.0%$-1.5M-386.1%-66.9%

Q3 2025

2025-09-30

$2.3M+8.2%$-263.4K-66.4%-11.7%

Q2 2025

2025-06-30

$2.2M-7.0%$-393.6K-32.1%-17.7%

Q1 2025

2025-03-31

$2.3M+5.7%$-292.7K-3.1%-12.9%

Q4 2024

2024-12-31

$1.9M$-312.8K-16.4%

Q3 2024

2024-09-30

$2.1M-22.6%$-158.3K-244.5%-7.6%

Q2 2024

2024-06-30

$2.4M+4.7%$-298.0K-22059.3%-12.5%

Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.

Industry trend

Laboratory Analytical Instruments · SIC 3826

Your notes

Keep private notes on LCTC — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to write a note

Insider activity

No insider transactions on file for LCTC in the last 12 months.

Source: SEC Form 4 filings. Backfill runs nightly.

Who owns LCTC

No institutional holdings on file for LCTC yet.

Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).

Top questions investors are asking

Coming once LCTC's latest filing finishes processing.